Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response

Marzia A.L. Romeo, Vittorio Martinelli, Gloria Dalla Costa, Bruno Colombo, Donatella De Feo, Federica Esposito, Laura Ferrè, Clara Guaschino, Simone Guerrieri, Giuseppe Liberatore, Filippo Martinelli Boneschi, Arianna Merlini, Mariajosè Messina, Roberta Messina, Arturo Nuara, Paolo Preziosa, Marta Radaelli, Maria A. Rocca, Mariaemma Rodegher, Francesca Sangalli & 3 others Davide Strambo, Lucia Moiola, Giancarlo Comi

Research output: Contribution to journalArticle

Abstract

Objective: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course. Materials and methods: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies. We have compared three large cohorts of patients with MS diagnosis, for three consecutive periods within July 2001, August 2001-December 2005, and January 2006-September 2011. Results: A total of 1068 relapsing-remitting pwMS cases were included. Patients in the last cohort began treatment earlier (P < 0.0001), started more frequent treatment with high-dose interferon beta or glatiramer acetate (P < 0.0001), and had experienced a more frequent treatment escalation strategy (P = 0.004) than patients in other cohorts. The multivariate analysis adjusted for baseline characteristics showed that pwMS of the last cohort had a high probability of showing no evidence of disease activity (NEDA3) at 4 years (OR 3.22, 95% CIs 1.89-5.47; P < 0.0001). These results were confirmed in a propensity score analysis. Conclusions: Our study showed an improvement over the last 15 years in the treatment response; this observation can be associated to a paradigm shift in MS treatment strategies.

Original languageEnglish
Pages (from-to)447-453
Number of pages7
JournalActa Neurologica Scandinavica
Volume138
Issue number5
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Multiple Sclerosis
Therapeutics
Propensity Score
Interferon-beta
Multivariate Analysis

Keywords

  • multiple sclerosis
  • no evidence of disease activity
  • paradigm shift treatment response

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. / Romeo, Marzia A.L.; Martinelli, Vittorio; Dalla Costa, Gloria; Colombo, Bruno; De Feo, Donatella; Esposito, Federica; Ferrè, Laura; Guaschino, Clara; Guerrieri, Simone; Liberatore, Giuseppe; Martinelli Boneschi, Filippo; Merlini, Arianna; Messina, Mariajosè; Messina, Roberta; Nuara, Arturo; Preziosa, Paolo; Radaelli, Marta; Rocca, Maria A.; Rodegher, Mariaemma; Sangalli, Francesca; Strambo, Davide; Moiola, Lucia; Comi, Giancarlo.

In: Acta Neurologica Scandinavica, Vol. 138, No. 5, 01.11.2018, p. 447-453.

Research output: Contribution to journalArticle

Romeo, Marzia A.L. ; Martinelli, Vittorio ; Dalla Costa, Gloria ; Colombo, Bruno ; De Feo, Donatella ; Esposito, Federica ; Ferrè, Laura ; Guaschino, Clara ; Guerrieri, Simone ; Liberatore, Giuseppe ; Martinelli Boneschi, Filippo ; Merlini, Arianna ; Messina, Mariajosè ; Messina, Roberta ; Nuara, Arturo ; Preziosa, Paolo ; Radaelli, Marta ; Rocca, Maria A. ; Rodegher, Mariaemma ; Sangalli, Francesca ; Strambo, Davide ; Moiola, Lucia ; Comi, Giancarlo. / Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. In: Acta Neurologica Scandinavica. 2018 ; Vol. 138, No. 5. pp. 447-453.
@article{d6c8b2c795f04c6bb8a5070a490e255e,
title = "Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response",
abstract = "Objective: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course. Materials and methods: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies. We have compared three large cohorts of patients with MS diagnosis, for three consecutive periods within July 2001, August 2001-December 2005, and January 2006-September 2011. Results: A total of 1068 relapsing-remitting pwMS cases were included. Patients in the last cohort began treatment earlier (P < 0.0001), started more frequent treatment with high-dose interferon beta or glatiramer acetate (P < 0.0001), and had experienced a more frequent treatment escalation strategy (P = 0.004) than patients in other cohorts. The multivariate analysis adjusted for baseline characteristics showed that pwMS of the last cohort had a high probability of showing no evidence of disease activity (NEDA3) at 4 years (OR 3.22, 95{\%} CIs 1.89-5.47; P < 0.0001). These results were confirmed in a propensity score analysis. Conclusions: Our study showed an improvement over the last 15 years in the treatment response; this observation can be associated to a paradigm shift in MS treatment strategies.",
keywords = "multiple sclerosis, no evidence of disease activity, paradigm shift treatment response",
author = "Romeo, {Marzia A.L.} and Vittorio Martinelli and {Dalla Costa}, Gloria and Bruno Colombo and {De Feo}, Donatella and Federica Esposito and Laura Ferr{\`e} and Clara Guaschino and Simone Guerrieri and Giuseppe Liberatore and {Martinelli Boneschi}, Filippo and Arianna Merlini and Mariajos{\`e} Messina and Roberta Messina and Arturo Nuara and Paolo Preziosa and Marta Radaelli and Rocca, {Maria A.} and Mariaemma Rodegher and Francesca Sangalli and Davide Strambo and Lucia Moiola and Giancarlo Comi",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/ane.12999",
language = "English",
volume = "138",
pages = "447--453",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response

AU - Romeo, Marzia A.L.

AU - Martinelli, Vittorio

AU - Dalla Costa, Gloria

AU - Colombo, Bruno

AU - De Feo, Donatella

AU - Esposito, Federica

AU - Ferrè, Laura

AU - Guaschino, Clara

AU - Guerrieri, Simone

AU - Liberatore, Giuseppe

AU - Martinelli Boneschi, Filippo

AU - Merlini, Arianna

AU - Messina, Mariajosè

AU - Messina, Roberta

AU - Nuara, Arturo

AU - Preziosa, Paolo

AU - Radaelli, Marta

AU - Rocca, Maria A.

AU - Rodegher, Mariaemma

AU - Sangalli, Francesca

AU - Strambo, Davide

AU - Moiola, Lucia

AU - Comi, Giancarlo

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Objective: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course. Materials and methods: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies. We have compared three large cohorts of patients with MS diagnosis, for three consecutive periods within July 2001, August 2001-December 2005, and January 2006-September 2011. Results: A total of 1068 relapsing-remitting pwMS cases were included. Patients in the last cohort began treatment earlier (P < 0.0001), started more frequent treatment with high-dose interferon beta or glatiramer acetate (P < 0.0001), and had experienced a more frequent treatment escalation strategy (P = 0.004) than patients in other cohorts. The multivariate analysis adjusted for baseline characteristics showed that pwMS of the last cohort had a high probability of showing no evidence of disease activity (NEDA3) at 4 years (OR 3.22, 95% CIs 1.89-5.47; P < 0.0001). These results were confirmed in a propensity score analysis. Conclusions: Our study showed an improvement over the last 15 years in the treatment response; this observation can be associated to a paradigm shift in MS treatment strategies.

AB - Objective: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course. Materials and methods: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies. We have compared three large cohorts of patients with MS diagnosis, for three consecutive periods within July 2001, August 2001-December 2005, and January 2006-September 2011. Results: A total of 1068 relapsing-remitting pwMS cases were included. Patients in the last cohort began treatment earlier (P < 0.0001), started more frequent treatment with high-dose interferon beta or glatiramer acetate (P < 0.0001), and had experienced a more frequent treatment escalation strategy (P = 0.004) than patients in other cohorts. The multivariate analysis adjusted for baseline characteristics showed that pwMS of the last cohort had a high probability of showing no evidence of disease activity (NEDA3) at 4 years (OR 3.22, 95% CIs 1.89-5.47; P < 0.0001). These results were confirmed in a propensity score analysis. Conclusions: Our study showed an improvement over the last 15 years in the treatment response; this observation can be associated to a paradigm shift in MS treatment strategies.

KW - multiple sclerosis

KW - no evidence of disease activity

KW - paradigm shift treatment response

UR - http://www.scopus.com/inward/record.url?scp=85050468246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050468246&partnerID=8YFLogxK

U2 - 10.1111/ane.12999

DO - 10.1111/ane.12999

M3 - Article

VL - 138

SP - 447

EP - 453

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 5

ER -